Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments.
Noemi Martínez-López-de-CastroMarisol Samartín-UchaAdolfo Paradela-CarreiroAntonio Pérez-LandeiroMaría Teresa Inaraja-BoboMiriam Álvarez-PayeroInés Castro-NúñezNerea García-BelosoDavid Robles-TorresAida López-LópezSonia González-CostasBelén Leboreiro-EnríquezLuis Otero-MillánElena Yaiza Romero-VentosaCristina Casanova-MartínezKarina Lorenzo-LorenzoAna María Regueira-ArcayCristina Vázquez-LópezCristina Martínez-RegleroGuadalupe Piñeiro-CorralesPublished in: Journal of clinical pharmacy and therapeutics (2020)
The number of pDDIs in patients admitted for COVID-19 in the first pandemic wave was remarkably high. However, clinical consequences occurred in a low percentage of patients. Interactions involving medications that would be contraindicated for concomitant administration are rare. Knowledge of these pDDIs and their consequences could help to establish appropriate therapeutic strategies in patients with COVID-19 or other diseases with these treatments.